BMY

Closing Bell for Wednesday on Wall Street: Markets Blunted on Fed Comments, Minutes

Closing Bell for Wednesday on Wall Street: Markets Open Soft, Close with a Flourish

Bristol-Myers Squibb Expansion to Add 350 Jobs

Drugmaker Bristol-Myers Squibb plans to spend about $250 million expanding a manufacturing complex it opened in 2009 for biologic treatments.

Top Analyst Upgrades and Downgrades (AMAG, AON, BMY, SCHW, COH, BVN, DF, GPS, HGG, LXK, MRK, KORS, NS, RRGB, TIF, TJX, YHOO)

Media Digest (3/4/2013) Reuters, WSJ, NYT, FT, Bloomberg

Eleven Must-Read Weekend Stock Stories for Monday

Pharma Merger/Buyout Hunt Continues in Biotech, Valuations Under Focus

JMP Securities Very Positive on Five Key Biotech Stocks (AMGN, BIIB, AFFY, ALNY, CELG, ONXX, PCYC, PFE, LLY, MRK, BMY)

Media Digest (2/1/2013) Reuters, WSJ, FT, Bloomberg

BofA/Merrill Lynch: Three Reasons to Own Stocks Now (GSK, BMY, SNY, ABBV, PM, MSFT, INTC, BP, KRFT, GE)

24/7 Wall St. Closing Bell — January 24, 2013: Markets Mixed After Apple Earnings (AAPL, PG, EMR, CVS, GOLD, TIF, AMGN, SNDK, FFIV, NE, NVR, WDC, MMM, BMY, LMT, RTN, LUV, UNP, UAL, XRX, T, JNPR, MSFT, SBUX, HAL, HON, KMB, WY, NOK, NFLX, SWFT)

24/7 Wall St. Closing Bell — January 23, 2013: Market Open Higher on Little News (COST, GE, VZ, F, INCY, AMD, CSX, GOOG, IBM, IGT, TXN, ABT, BHI, COH, GD, MCD, LCC, AAPL, AMGN, NFLX, SNDK, FFIV, NE, NVR, WDC, MMM, BMY, LMT, RYN, LUV, UNP, UAL, XRX, M

Bristol-Myers Squibb Earnings Top Estimates

Bristol-Myers Squibb, which sells blood thinner Plavix, today reported better-than-expected third quarter earnings, mainly due to cost cuts. Revenue, however, fell short of expectations, and shares are down in trading Tuesday.

Amgen's troubles keep compounding; Aranesp studies reveal greater risks

AstraZeneca and Boehringer present bloodthinner alternatives

Animal rights groups step up attacks against Novartis

Bristol - Myers buyout of Medarex

AstraZeneca wants a piece of the multi-billion bloodthinner market

GlaxoSmithKline, Pfizer join to fight HIV

The Merck deal is driven by politics - and fear